Header Logo

Connection

SETH LERNER to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications SETH LERNER has written about Biomarkers, Tumor.
SETH LERNER
Connection Strength
3.422
Biomarkers, Tumor
  1. SIU-ICUD consultation on bladder cancer: basic science. World J Urol. 2019 Jan; 37(1):15-29.
    View in: PubMed
    Score: 0.369
  2. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int. 2012 Sep; 110(5):630-6.
    View in: PubMed
    Score: 0.230
  3. Molecular markers in bladder cancer. Curr Opin Urol. 2008 Jan; 18(1):1-8.
    View in: PubMed
    Score: 0.173
  4. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol. 2005 Jul; 48(1):69-76.
    View in: PubMed
    Score: 0.142
  5. Alternatives to cytology in the management of non-muscle invasive bladder cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):377-89.
    View in: PubMed
    Score: 0.138
  6. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
    View in: PubMed
    Score: 0.132
  7. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):626-30.
    View in: PubMed
    Score: 0.132
  8. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol. 2003 Dec; 170(6 Pt 1):2244-7.
    View in: PubMed
    Score: 0.130
  9. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003 Dec; 170(6 Pt 1):2248-52.
    View in: PubMed
    Score: 0.130
  10. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
    View in: PubMed
    Score: 0.109
  11. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001 Jan-Feb; 21(1B):575-8.
    View in: PubMed
    Score: 0.106
  12. Re: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol. 2000 Nov; 164(5):1670.
    View in: PubMed
    Score: 0.105
  13. Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila). 2017 Oct; 10(10):588-597.
    View in: PubMed
    Score: 0.084
  14. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
    View in: PubMed
    Score: 0.083
  15. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 10; 72(4):544-554.
    View in: PubMed
    Score: 0.082
  16. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol. 2017 09; 72(3):354-365.
    View in: PubMed
    Score: 0.082
  17. Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017 01 19; 7:40714.
    View in: PubMed
    Score: 0.081
  18. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
    View in: PubMed
    Score: 0.080
  19. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017 Mar 01; 123(5):794-801.
    View in: PubMed
    Score: 0.080
  20. Diagnostic and Prognostic Markers in Bladder Cancer. Dis Markers. 2016; 2016:2425091.
    View in: PubMed
    Score: 0.079
  21. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol. 2017 02; 71(2):237-246.
    View in: PubMed
    Score: 0.079
  22. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. J Urol. 2016 06; 195(6):1911-9.
    View in: PubMed
    Score: 0.075
  23. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7.
    View in: PubMed
    Score: 0.074
  24. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010 Jun; 56(6):e1-48.
    View in: PubMed
    Score: 0.050
  25. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010 Jan; 183(1):68-75.
    View in: PubMed
    Score: 0.050
  26. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009 Jan 21; 101(2):114-9.
    View in: PubMed
    Score: 0.046
  27. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008 Jan 15; 112(2):315-25.
    View in: PubMed
    Score: 0.043
  28. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.039
  29. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. Expert Rev Anticancer Ther. 2006 Feb; 6(2):281-91.
    View in: PubMed
    Score: 0.038
  30. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 Oct 01; 7(10):e2437871.
    View in: PubMed
    Score: 0.034
  31. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
    View in: PubMed
    Score: 0.034
  32. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.
    View in: PubMed
    Score: 0.033
  33. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer. 2003 Sep 20; 106(5):661-5.
    View in: PubMed
    Score: 0.032
  34. Circulating and urinary tumour DNA in urothelial carcinoma?- upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 07; 20(7):406-419.
    View in: PubMed
    Score: 0.031
  35. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
    View in: PubMed
    Score: 0.031
  36. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
    View in: PubMed
    Score: 0.028
  37. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001 May; 12(5):621-5.
    View in: PubMed
    Score: 0.027
  38. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441.
    View in: PubMed
    Score: 0.027
  39. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891.
    View in: PubMed
    Score: 0.025
  40. Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. Clin Cancer Res. 2019 06 15; 25(12):3689-3701.
    View in: PubMed
    Score: 0.023
  41. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. Eur Urol. 2015 Aug; 68(2):238-53.
    View in: PubMed
    Score: 0.018
  42. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A. 2012 Feb 07; 109(6):2078-83.
    View in: PubMed
    Score: 0.014
  43. Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol. 2005 Apr; 29(4):443-51.
    View in: PubMed
    Score: 0.009
  44. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003 May; 61(5):1053-8.
    View in: PubMed
    Score: 0.008
  45. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.